All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

Sanofi's assault on Aventis galvanises capital markets

Sanofi-Synthélabo, the French pharmaceuticals company, lit up the bond, equity and loan markets this week by launching a Eu47.8bn hostile bid for its competitor, Aventis.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree